Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855372 | 0.83 | ALDH1A1 (0.39) | CDC7DBF4NOS3NOS2MEN1 | |
| SCHEMBL13848218 | 0.83 | NOS3 (0.32) | CDC7DBF4NOS3NOS2 | |
| SCHEMBL23264082 | 0.79 | GCGR (0.37) | NOS3NOS2 | |
| SCHEMBL24262442 | 0.79 | YTHDC1 (0.39) | CDC7DBF4NOS3NOS2MEN1 | |
| SCHEMBL25463299 | 0.79 | PDPK1 (0.36) | NOS3NOS2MEN1KMT2AALDH1A1 | |
| SCHEMBL23264073 | 0.79 | ALDH1A1 (0.38) | NOS3NOS2NOTUMALDH1A1HPGD | |
| SCHEMBL25467306 | 0.79 | CYP1A2 (0.37) | NOS3NOS2MEN1KMT2AALDH1A1 | |
| SCHEMBL21895750 | 0.78 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL20196815 | 0.76 | CHRM4 (0.34) | — | |
| SCHEMBL14367975 | 0.76 | KDM5B (0.31) | KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-9527843-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9067921-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20120065397-A1 | PREPARATION OF KETONE AMIDES | Scherimg Corporation (US) | 2012-03-15 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7759487-B2 | Preparation of ketone amides | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100029939-A1 | PREPARATION OF KETONE AMIDES | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080095740-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7307081-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7276617-B2 | Organometallic complex, luminescent solid, organic EL element and organic EL display | FUJIFILM CORPORATION (JP) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344474-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD1, DRD2, DRD3 | CDC7 2936/4885DBF4 3632/4885NOS3 1445/4885 |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CDC7 4220/4885DBF4 3084/4885NOS3 436/4885 |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | CDC7 850/4885DBF4 1314/4885NOS3 4364/4885 |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | CDC7 2730/4885DBF4 1023/4885NOS3 50/4885 |
| US-20100029939-A1 | PREPARATION OF KETONE AMIDES | CCR5, CCR2, ACKR3 | CDC7 1752/4885DBF4 2081/4885NOS3 1604/4885 |
| US-20120065397-A1 | PREPARATION OF KETONE AMIDES | CCR5, CCR2, ACKR3 | CDC7 1752/4885DBF4 2081/4885NOS3 1604/4885 |
| US-20080095740-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | CDC7 4433/4885DBF4 2549/4885NOS3 736/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CDC7 752/4885DBF4 2490/4885NOS3 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.